Background Despite the long-standing recommendations of high-protein diets for patients with cancer, the precise mechanisms of this dietary approach in benefiting tumour suppression and enhancing ...

A new review in Genes and Diseases explores the central role of MYC, a master regulatory protein, in the development and progression of cancer, spotlighting its potential as a multidimensional ...

A new review in Genes and Diseases explores the central role of MYC, a master regulatory protein, in the development and progression of cancer ...

Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapies, cancer genomics, using AI to personalize cancer treatment, improving diagnosis of hard-to-treat ...

A new review in Genes and Diseases explores the central role of MYC, a master regulatory protein, in the development and ...

If the agency approves its application, the firm will begin a Phase I clinical trial in c-MYC-driven cancers in 2026.

UTR Therapeutics Inc. has submitted an IND application to the FDA for UTRxM1-18, a novel therapeutic approach for targeting c-MYC-driven cancers. Pending approval, a first-in-human phase I trial is ...

Colorectal cancer is the third most diagnosed type of cancer worldwide. Up to 80% of the cases are related to environmental ...

BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ...

Plasmodium falciparum infection increases the risk of Burkitt lymphoma (cancer) in children by triggering enzyme changes that ...

Burkitt lymphoma, a cancer that impacts a subset of immune cells called B cells, develops most often in children and young adults.  Patients with Burk | Cancer ...

May 2025 brings Cancer a blend of challenges and harmony. Initial concerns about family and work give way to domestic bliss and spiritual growth. Professional progress is achieved through ...